GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » Institutional Ownership

Check-Cap (Check-Cap) Institutional Ownership : 0.20% (As of May. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Check-Cap Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Check-Cap's institutional ownership is 0.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Check-Cap's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Check-Cap's Float Percentage Of Total Shares Outstanding is 99.84%.


Check-Cap Institutional Ownership Historical Data

The historical data trend for Check-Cap's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap Institutional Ownership Chart

Check-Cap Historical Data

The historical data trend for Check-Cap can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.05 0.05 0.05 0.30 0.30 0.30 0.30 0.20 0.20 0.20

Check-Cap Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Check-Cap (Check-Cap) Business Description

Traded in Other Exchanges
Address
29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.